Overview
The purpose of this study is to collect data on how advanced and rare cancers respond to biomarker-based treatments.
Description
The UNIQUE umbrella protocol is an overarching framework to study precision medicine in patients with precise molecular data, who have exhausted all established treatment options and who are not eligible for any of the ongoing trials. There is no additional visit or procedure required to participate in this study. Participants who have received/who may receive the following treatments may join the study and will be assigned to a study cohort (group):
- Group 1 - Health Canada approved/marketed drug(s) used on or off-label as Standard of Care (SOC)
- Group 2 - Drugs accessed from Special Access Program (SAP)
- Group 3 - Non-marketed investigational agents
Under the UNIQUE framework, data from participants will be evaluated. The following data will be collected:
- Demographic data (for example: sex, race, month and year of birth)
- Medical history
- Cancer characteristics including biomarkers
- Treatment history
- response to treatment
Eligibility
Inclusion Criteria & Exclusion Criteria:
Patient's existing genomic information from tumor molecular profiling will be discussed in
the hospital expert molecular tumor board rounds consisting of representatives from
specialist genomic profiling and medical oncology departments to decide N of 1 treatment
for the patient. The discussion will surround the best next therapeutic option in the
patient's cancer subtype with or without clear standard of care guidelines. Therefore,
specific eligibility criteria aside from individual patient's medical history is not
applicable.